Alongside Alkeus, companies like Belite Bio, Ocugen and Nanoscope are aiming to secure a place on the Stargardt market with no approved drugs.

Mediar Therapeutics has announced a collaboration and option agreement with Ono Pharmaceutical to develop treatments for fibro-inflammatory diseases.

Pfizer emerged as a pharmaceutical powerhouse during the pandemic, but lower infection rates and narrower use cases mean its Covid-19 brands are impacting the company’s bottom l ...

CapVest Partners-backed Curium has agreed to acquire rival US-based radiopharmaceutical company Lantheus in an all-cash deal worth up to nearly $8bn.

Eli Lilly has lifted its full-year outlook for the second time this year on the back of another strong quarter, indicating it is far from relinquishing its dominant position as pace setter on the ...

Evotec and Odyssey Therapeutics have announced a strategic AI-enabled R&D partnership to explore new treatments for autoimmune and inflammatory diseases.

Philadelphia-based biotech Context Therapeutics has terminated the development programme for one of its pipeline bispecific T-cell engagers (BiTEs) as the company looks to cut cos ...

Scottish biopharmaceutical company Mironid has pocketed $46m in Series B funding raise to progress the development of its lead rare kidney disease candidate. The financing, which ...

An AstraZeneca spokesperson declined to comment, while BMS did not immediately respond. Credit: Robert Way/Shutterstock.com. Shares in AstraZeneca dropped by nearly 3% at market open after a report ...

Set against the backdrop of a mixed Q2, Novo Nordisk is eyeing bolt-ons in favour of transformative acquisitions.

GlobalData previously flagged Orzeyful’s approval in narcolepsy as a key Q3 catalyst for pharma due to the drug’s ‘transformative’ potential.

Biologics CDMO AsymBio is set to secure $184m in funding from Asymchem Group, Hillhouse Qirui and other investors to support long-term growth.